瑞舒伐他汀与氟伐他汀对冠心病调脂效果的对比研究

Comparative of Rosuvastatin and fluvastatin on Regulating Lipid Effects in Patients with Coronary Heart Disease

目的比较瑞舒伐他汀与氟伐他汀对冠心病的调脂效果。方法选取2012年12月—2013年7月在我院采用瑞舒伐他汀进行治疗的冠心病患者333例作为瑞舒伐他汀组,选取2012年在我院采用氟伐他汀进行治疗的冠心病患者320例作为氟伐他汀组。测量两组患者治疗前后三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)及超敏C反应蛋白(hs-CRP)水平。结果治疗2周后瑞舒伐他汀组患者TC、TG、LDL-C及hs-CRP水平均低于氟伐他汀组,HDL-C水平高于氟伐他汀组(P<0.05);两组患者在治疗期间均未出现严重不良反应。结论瑞舒伐他汀与氟伐他汀相比,调脂效果更为显著,且安全。

Objective To compare the regulating lipid effects of rosuvastatin and fluvastatin on patients with coronary heart disease. Methods 333 patients with coronary heart disease in my hospital with rosuvastatin treatment were selected as the rosuvastatin group from December 2012 to July 2013, 320 patients with coronary heart disease in my hospital with fluvastatin treatment were selected as the fluvastatin group in 2012. The level of triglyceride （TG）, total cholesterol （TC）, high density lipoprotein cholesterol （ HDL - C）, low density lipoprotein cholesterol （ LDL - C） and high - sensitivity C - reactive protein （hs - CRP） were measured before and after treatment. Results After treatment for 2 weeks, the levels of TC, TG, LDL - C and hs - CRP in Rosuvastatin group were lower than those of fluvastatin group, HDL - C levels was higher than that of fluvastatin group （P 〈0. 05） ; The patients of two groups were no serious adverse reactions during treatment. Conclusion Rosuvastatin compared with fluvastatin, regulating lipid effect is more significant, and safe.